Analysts' Actions -- Biogen, GoPro, L Brands, Time Warner and More

RATINGS CHANGES

Akorn (AKRX) was downgraded to underperform from buy at Bank of America/Merrill Lynch. $22 price target. The company is facing potential risks on several fronts, analysts said. 

Biogen (BIIB) was upgraded to overweight from neutral at Piper Jaffray. $335 price target. The valuation is reasonable, given opportunities in Alzheimer's and SMA, Piper said. 

BioMarin (BMRN) was downgraded to neutral from overweight at Piper Jaffray. $84 price target. The valuation is less attractive, given limited visibility, Piper said. 

Ford (F) was downgraded to hold at TheStreet Ratings. You can view the full analysis from the report here: F.

GoPro (GPRO) was downgraded to underperform from buy at Bank of America/Merrill Lynch. $10 price target. Earnings estimates were also cut, given the company's new guidance, analysts said. 

Impax (IPXL) was downgraded to underperform from neutral at Bank of America/Merrill Lynch. $19 price target. The company may miss 2016 targets, analysts said. 

ITT (ITT) was upgraded to overweight from sector weight at Keybanc. The valuation is more attractive, based on a $40 price target, Keybanc said. 

L Brands (LB) was downgraded to underperform at Jefferies. $50 price target. The company is facing increased competition and earnings are now expected to decline in 2018, Jefferies said. 

Parker Hannifin (PH) was upgraded to overweight at Morgan Stanley. $139 price target. The company is reasonably valued and can delivery above-average earnings growth in the coming quarters, Morgan Stanley said. 

Premier (PINC) was downgraded underperform from buy at Bank of America/Merrill Lynch. $30 price target. The specialty pharma business is posing greater risk, analysts said. 

Take-Two Interactive Software (TTWO) was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: TTWO.

Time Warner (TWX) was upgraded to outperform from neutral at Credit Suisse. $107.50 price target. Regulatory pessimism appears overdone, Credit Suisse said. 

Xerox (XRX) was downgraded to underweight at Morgan Stanley. $9.50 price target. BPO and document technology performance remains weak, Morgan Stanley said. 

This article was written by a staff member of TheStreet.

If you liked this article you might like

Teva, Mylan Seen to Stay on M&A Sidelines

Teva, Mylan Seen to Stay on M&A Sidelines

Merger Buzz Drives Akorn to Top of Health Chart in April

Merger Buzz Drives Akorn to Top of Health Chart in April

Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up

Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up

European Stocks High on French Perfume and Trump Bump

European Stocks High on French Perfume and Trump Bump

Analysts' Actions -- Amazon, C.R. Bard, CyrusOne, Dow and More

Analysts' Actions -- Amazon, C.R. Bard, CyrusOne, Dow and More